Table of Contents
ISRN Oncology
Volume 2011, Article ID 670358, 6 pages
http://dx.doi.org/10.5402/2011/670358
Clinical Study

No Prognostic Impact of p53 and P-Glycoprotein Expression in Patients with Diffuse Large B-Cell Lymphoma

1Department of Pathology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand
2Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand
3Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand

Received 15 August 2011; Accepted 18 September 2011

Academic Editor: G. Schiavon

Copyright © 2011 Pairaya Rujirojindakul et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Sukpanichnant, “Analysis of 1983 cases of malignant lymphoma in Thailand according to the World Health Organization classification,” Human Pathology, vol. 35, no. 2, pp. 224–230, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Coiffier, E. Lepage, J. Briere et al., “Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma,” The New England Journal of Medicine, vol. 346, no. 4, pp. 235–242, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Feugier, A. Van Hoof, C. Sebban et al., “Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the groupe d'etude des lymphomes de l'adulte,” Journal of Clinical Oncology, vol. 23, no. 18, pp. 4117–4126, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. “A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project,” The New England Journal of Medicine, vol. 329, no. 14, pp. 987–994, 1993.
  5. M. Ziepert, D. Hasenclever, E. Kuhnt et al., “Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era,” Journal of Clinical Oncology, vol. 28, no. 14, pp. 2373–2380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. S. A. Amundson, T. G. Myers, and A. J. Fornace, “Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress,” Oncogene, vol. 17, no. 25, pp. 3287–3299, 1998. View at Google Scholar · View at Scopus
  7. C. Nieder, S. Petersen, C. Petersen, and H. D. Thames, “The challenge of p53 as prognostic and predictive factor in Hodgkin's or non-Hodgkin's lymphoma,” Annals of Hematology, vol. 80, no. 1, pp. 2–8, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Ling, “P-glycoprotein and resistance to anticancer drugs,” Cancer, vol. 69, no. 10, pp. 2603–2609, 1992. View at Google Scholar · View at Scopus
  9. A. R. Yuen and B. I. Sikic, “Multidrug resistance in lymphomas,” Journal of Clinical Oncology, vol. 12, no. 11, pp. 2453–2459, 1994. View at Google Scholar · View at Scopus
  10. Q. Liu, K. Ohshima, and M. Kikuchi, “High expression of MDR-1 gene and P-glycoprotein in initial and re-biopsy specimens of relapsed B-cell lymphoma,” Histopathology, vol. 38, no. 3, pp. 209–216, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Ohsawa, Y. Ikura, H. Fukushima et al., “Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma,” Oncology, vol. 68, no. 4–6, pp. 422–431, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Leroy, C. Haioun, E. Lepage et al., “p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas,” Annals of Oncology, vol. 13, no. 7, pp. 1108–1115, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Visco, F. Canal, C. Parolini et al., “The impact of P53 and P21waf1 expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma,” Haematologica, vol. 91, no. 5, pp. 687–690, 2006. View at Google Scholar · View at Scopus
  14. C. C. Chang, Y. C. Liu, R. P. Cleveland, and S. L. Perkins, “Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas,” American Journal of Clinical Pathology, vol. 113, no. 4, pp. 512–518, 2000. View at Google Scholar · View at Scopus
  15. J. H. Paik, Y. K. Jeon, S. S. Park et al., “Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas,” Histopathology, vol. 47, no. 3, pp. 281–291, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. M. H. H. Kramer, J. Hermans, J. Parker et al., “Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study,” Journal of Clinical Oncology, vol. 14, no. 7, pp. 2131–2138, 1996. View at Google Scholar · View at Scopus
  17. M. Llanos, H. Alvarez-Argüelles, R. Alemán, J. Oramas, L. Díaz-Flores, and N. Batista, “Prognostic significance of ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large b-cell lymphoma,” Medical Oncology, vol. 18, no. 1, pp. 15–22, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Colomo, A. López-Guillermo, M. Perales et al., “Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma,” Blood, vol. 101, no. 1, pp. 78–84, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. M. A. Piris, F. Pezella, J. C. Martinez-Montero et al., “p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time,” British Journal of Cancer, vol. 69, no. 2, pp. 337–341, 1994. View at Google Scholar · View at Scopus
  20. L. Stefancikova, M. Moulis, P. Fabian et al., “Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma,” International Journal of Oncology, vol. 39, no. 6, pp. 1413–1420, 2011. View at Google Scholar
  21. A. A. Alizadeh, M. B. Eisen, R. E. Davis et al., “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling,” Nature, vol. 403, no. 6769, pp. 503–511, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Rosenwald, G. Wright, W. C. Chan et al., “The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma,” The New England Journal of Medicine, vol. 346, no. 25, pp. 1937–1947, 2002. View at Publisher · View at Google Scholar · View at Scopus